DE19939095A1 - Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer - Google Patents
Von Coxsackieviren abgeleitetes Vektorsystem für GentransferInfo
- Publication number
- DE19939095A1 DE19939095A1 DE19939095A DE19939095A DE19939095A1 DE 19939095 A1 DE19939095 A1 DE 19939095A1 DE 19939095 A DE19939095 A DE 19939095A DE 19939095 A DE19939095 A DE 19939095A DE 19939095 A1 DE19939095 A1 DE 19939095A1
- Authority
- DE
- Germany
- Prior art keywords
- rna molecule
- genome
- dna
- plasmid
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 88
- 239000013598 vector Substances 0.000 title claims abstract description 80
- 241000709687 Coxsackievirus Species 0.000 title claims abstract description 16
- 238000012546 transfer Methods 0.000 title description 16
- 239000013612 plasmid Substances 0.000 claims abstract description 69
- 208000015181 infectious disease Diseases 0.000 claims abstract description 50
- 210000002845 virion Anatomy 0.000 claims abstract description 39
- 230000002458 infectious effect Effects 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 104
- 210000004027 cell Anatomy 0.000 claims description 84
- 241000700605 Viruses Species 0.000 claims description 40
- 108020004414 DNA Proteins 0.000 claims description 28
- 239000002299 complementary DNA Substances 0.000 claims description 19
- 238000001415 gene therapy Methods 0.000 claims description 12
- 241000701161 unidentified adenovirus Species 0.000 claims description 12
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 238000001890 transfection Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 108090000565 Capsid Proteins Proteins 0.000 claims description 5
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 4
- 108060004795 Methyltransferase Proteins 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 241000450599 DNA viruses Species 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 101710172711 Structural protein Proteins 0.000 claims description 3
- 231100001083 no cytotoxicity Toxicity 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 101800001065 Protein 2B Proteins 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 241000709675 Coxsackievirus B3 Species 0.000 description 29
- 230000010076 replication Effects 0.000 description 14
- 230000014616 translation Effects 0.000 description 11
- 238000013519 translation Methods 0.000 description 11
- 210000004413 cardiac myocyte Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 210000004165 myocardium Anatomy 0.000 description 7
- 230000010415 tropism Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 241000991587 Enterovirus C Species 0.000 description 5
- 108010076039 Polyproteins Proteins 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 238000001638 lipofection Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- 101800001494 Protease 2A Proteins 0.000 description 3
- 101800001491 Protease 3C Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000020004 porter Nutrition 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 101150039504 6 gene Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100256850 Drosophila melanogaster EndoA gene Proteins 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000696272 Gull adenovirus Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101710188314 Protein V Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000030498 cytoplasmic translation Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000021 endosomolytic effect Effects 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- MVMXJBMAGBRAHD-UHFFFAOYSA-N picoperine Chemical compound C=1C=CC=NC=1CN(C=1C=CC=CC=1)CCN1CCCCC1 MVMXJBMAGBRAHD-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 241000897111 recombinant polioviruses Species 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32341—Use of virus, viral particle or viral elements as a vector
- C12N2770/32343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- - Bereitstellen eines RNA-Moleküls oder eines Virions der obengenannten Art, und
- - Infizieren der Zielzelle mit dem Virion bzw. Übertragung des RNA-Moleküls durch Transfektion.
- - Transfizieren von Wirtszellen mit dem erfindungsgemäßen Vektorplasmid, und
- - Komplementieren der ausgetauschten Sequenzen in der Wirts zelle durch das erfindungsgemäße Helfer-Konstrukt.
- a) Bereitstellen einer für infektiöse CVE, vorzugsweise CVB3, kodierenden cDNA,
- b) Klonieren der cDNA auf transkribierbare Weise in ein Plas mid,
- c) Verstärken von Sequenzabschnitten des Plasmides mit Hilfe von Primern, die zu einem Amplifikat führen, das für das nicht-infektiöse Virusgenom kodiert, und
- d) Ligieren des Amplifikates mit einer DNA-Sequenz für das Fremdgen.
- a) Bereitstellen einer für infektiöse CVB, vorzugsweise CVB3 kodierenden cDNA,
- b) Klonieren der cDNA auf transkribierbare Weise in ein Plas mid, und
- c) Verstärken von Sequenzabschnitten des Plasmides mit Hilfe von Primern, die zu einem Amplifikat führen, das für die ausgetauschten kodierenden Sequenzen kodiert.
- - einem Plasmid mit klonierter cDNA für infektiöse CVB, vor zugsweise CVB3, und
- - den erforderlichen Primern für die Amplifikation von Se quenzabschnitten zur Erzeugung des Vektorplasmides und/oder des Helfer-Konstruktes, bzw.
- - fertigen, geprüften DNA-Amplifikaten.
Die Gruppe A mit 23 Serotypen und die Gruppe B mit 6 Serotypen.
5'-TTT GCT GTA TTC AAC TTA ACA ATG AAT TGT AAT GTT TTA ACC-3'
5'-ATG GCT GAA CGC CAA AAC AAT AGC TGG C-3'
5'-GAT GCA ATG GAA CAG GGA GTG AAG GAC TAT G-3'
5'-TAG ATT AGA GAC AAT TTG AAA TAA TTT AGA TTG GC-3'
5'-A GAC TCT AGA CAG CAA AAT GGG AGC TCA AGT ATC AAC GC-3'
sowie SEQ ID Nr. 6 verwendet:
5'-A TAT GCG GCC GCC TAA AAT GCG CCC GTA T'IT GTC ATT GTA GTG NEC C-3'
5'-A TAT GCG GCC GCC AGC AM ATG GGA CAA CAA TCA GGG GCA GIG TAT GTG G-3'
oder SEQ ID Nr. 8
5'-CTT AAG ATG GGA CAA CAA TCA GGG GCA GTG TAT-3'
als Forward-Primer und als Reverse-Primer SEQ ID Nr. 9 einge setzt:
5'-A TAT GGG CCC CTA CTG TTC CAT TGC ATC ATC TTC CAG C-3'
5'-A TAT GCG GCC GCC AGC AAA ATG GGA GB3 AAG GAC TAT GIG GAA CAG C-3'
sowie der Primer SEQ ID Nr. 11 eingesetzt:
5'-A TAT GGG CCC CTA TTG GCG TTC AGC CAT AGG GAT TCC G-3'
5'-A TAT GCG GCC GCC AGC AAA ATG GGA GTC AAG GAC TAT GIG GAA CAG C-3'
sowie der Primer SEQ ID Nr. 13 eingesetzt:
5'-A TAT GGG CCC CTA AAA GGA GTC CAA CCA CTT CCT GCG-3'.
Claims (32)
- - Bereitstellen eines RNA-Moleküles nach einem der An sprüche 1 bis 7 oder eines Virions nach Anspruch 9 oder 10, und
- - Infizieren der Zielzelle mit dem Virion bzw. Über tragung des RNA-Moleküls durch Transfektion.
- - Transfizieren von Wirtszellen mit dem Vektorplasmid nach Anspruch 12, und
- - Komplementieren der ausgetauschten Sequenzen in der Wirtszelle durch das Helfer-Konstrukt nach einem der Ansprüche 13 bis 15.
- a) Bereitstellen einer für infektiöse Coxsackieviren der Subgruppe B, vorzugsweise der Subgruppe B3 ko dierenden cDNA,
- b) Klonieren der cDNA auf transkribierbare Weise in ein Plasmid,
- c) Verstärken von Sequenzabschnitten des Plasmides mit Hilfe von Primern, die zu einem Amplifikat führen, das für das nicht-infektiöse Virusgenom kodiert, und
- d) Ligieren des Amplifikates mit einer DNA-Sequenz für das Fremdgen.
- a) Bereitstellen einer für infektiöse Coxsackieviren der Subgruppe H, vorzugsweise H3 kodierenden cDNA,
- b) Klonieren der cDNA auf transkribierbare Weise in ein Plasmid, und
- c) Verstärken von Sequenzabschnitten des Plasmides mit Hilfe von Primern, die zu einem Amplifikat führen, das für die ausgetauschten, kodierenden Sequenzen kodiert.
- 1. einem Plasmid mit klonierter cDNA für infektiöse Coxsackieviren der Subgruppe B, vorzugsweise der Subgruppe B3, und
- 2. den erforderlichen Primern für die Amplifikation.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19939095A DE19939095A1 (de) | 1999-08-18 | 1999-08-18 | Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer |
JP2001516902A JP2003507014A (ja) | 1999-08-18 | 2000-08-10 | コクサッキーウイルス類由来の遺伝子導入ベクター系 |
AU62816/00A AU6281600A (en) | 1999-08-18 | 2000-08-10 | Coxsackie virus-derived vector system for gene transfer |
EP00949478A EP1210439A1 (de) | 1999-08-18 | 2000-08-10 | Von coxsackieviren abgeleitetes vektorsystem für gentransfer |
PCT/EP2000/007768 WO2001012815A1 (de) | 1999-08-18 | 2000-08-10 | Von coxsackieviren abgeleitetes vektorsystem für gentransfer |
CA002382090A CA2382090A1 (en) | 1999-08-18 | 2000-08-10 | Coxsackie virus-derived vector system for gene transfer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19939095A DE19939095A1 (de) | 1999-08-18 | 1999-08-18 | Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19939095A1 true DE19939095A1 (de) | 2001-02-22 |
Family
ID=7918752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19939095A Withdrawn DE19939095A1 (de) | 1999-08-18 | 1999-08-18 | Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1210439A1 (de) |
JP (1) | JP2003507014A (de) |
AU (1) | AU6281600A (de) |
CA (1) | CA2382090A1 (de) |
DE (1) | DE19939095A1 (de) |
WO (1) | WO2001012815A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
CN103261424B (zh) * | 2010-12-16 | 2017-12-12 | 巴斯夫农业公司 | 对除草剂具有增强的耐受性的植物 |
AR091489A1 (es) | 2012-06-19 | 2015-02-11 | Basf Se | Plantas que tienen una mayor tolerancia a herbicidas inhibidores de la protoporfirinogeno oxidasa (ppo) |
US10041087B2 (en) | 2012-06-19 | 2018-08-07 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
EP3033419A4 (de) | 2013-08-12 | 2017-07-05 | BASF Agro B.V. | Pflanzen mit erhöhter toleranz gegen herbizide |
AU2014307660A1 (en) | 2013-08-12 | 2016-03-03 | Basf Agro B. V. | Plants having increased tolerance to herbicides |
CN107760719B (zh) * | 2017-10-24 | 2020-09-22 | 北京领柯生物科技有限公司 | 柯萨奇病毒在过继免疫基因递送系统中的应用 |
WO2023077484A1 (zh) * | 2021-11-06 | 2023-05-11 | 江汉大学 | 一种5种人肠病毒的mnp标记组合、引物对组合、试剂盒及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998039426A2 (en) * | 1997-03-05 | 1998-09-11 | University Of Nebraska Board Of Regents | Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US606385A (en) * | 1898-06-28 | Thirds to george h |
-
1999
- 1999-08-18 DE DE19939095A patent/DE19939095A1/de not_active Withdrawn
-
2000
- 2000-08-10 AU AU62816/00A patent/AU6281600A/en not_active Abandoned
- 2000-08-10 CA CA002382090A patent/CA2382090A1/en not_active Abandoned
- 2000-08-10 WO PCT/EP2000/007768 patent/WO2001012815A1/de not_active Application Discontinuation
- 2000-08-10 EP EP00949478A patent/EP1210439A1/de not_active Withdrawn
- 2000-08-10 JP JP2001516902A patent/JP2003507014A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998039426A2 (en) * | 1997-03-05 | 1998-09-11 | University Of Nebraska Board Of Regents | Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products |
Also Published As
Publication number | Publication date |
---|---|
JP2003507014A (ja) | 2003-02-25 |
WO2001012815A1 (de) | 2001-02-22 |
CA2382090A1 (en) | 2001-02-22 |
AU6281600A (en) | 2001-03-13 |
EP1210439A1 (de) | 2002-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11932668B2 (en) | Selective recovery | |
DE60117550T2 (de) | Doppelsträngige parvovirus-vektoren | |
DE69634904T2 (de) | Negativstrand rna virus mit selbständiger replikationsaktivität | |
DE69021575T3 (de) | Expressionssysteme für rekombinante negativstrang-rna-viren und impfstoffe. | |
EP1851239B1 (de) | Replikationsdefiziente rna-viren als impfstoffe | |
WO2003033700A1 (de) | Verfahren zur hemmung der replikation von viren | |
EP1151123A1 (de) | Verfahren zur herstellung eines rekombinanten adeno-assoziierten virus, geeignete mittel hierzu sowie verwendung zur herstellung eines arzneimittels | |
DE10066104A1 (de) | Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung | |
DE19939095A1 (de) | Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer | |
DE69836499T2 (de) | Virus mit membranmutationen für ein witsspektrum und deren verwendung als vakzinsubstrat | |
JP4430543B2 (ja) | 日本脳炎ウイルスの全長のゲノムRNA及び該JEVゲノムRNAに対する感染性を有するJEVcDNA及びその用途 | |
CN101405033A (zh) | 增强感染性细小病毒载体在昆虫细胞中的生产 | |
EP2430167B1 (de) | Aslv-vektorsystem | |
US7208315B2 (en) | Compositions and methods for efficient AAV vector production | |
Liu et al. | Tolerance of Senecavirus A to mutations in its kissing-loop or pseudoknot structure computationally predicted in 3′ untranslated region | |
DE69001689T2 (de) | Attenuierte viren. | |
EP1235912B1 (de) | Tumorspezifischer vektor für die gentherapie | |
DE60118456T2 (de) | Pestvirus Mutanten und diese enthaltende Impfstoffe | |
DE69636456T2 (de) | In-vitro verpackung von adeno-assoziierten virus dns | |
EP1173595A1 (de) | Verwendung von coxsackieviren zur verbesserung der transfektion von zellen | |
EP1149171B1 (de) | Foamy-virus-vektoren zur expression von fremdgenen in säugern und deren verwendung | |
EP1412509B1 (de) | Rna-amplifikationssystem mit komponenten aus der pflanze in tierischen zellen | |
DE69834813T2 (de) | Parvovirus-Vektoren und deren Verwendung | |
Mishra et al. | Maxizyme-mediated suppression of chikungunya virus replication and transmission in transgenic Aedes aegypti mosquitoes | |
DE10056210A1 (de) | Virales Expressionssystem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8181 | Inventor (new situation) |
Inventor name: KUEPPER, JAN-HEINER, DR., 72127 KUSTERDINGEN, DE Inventor name: MEYER, RALPH, DR., 55596 WALDBOECKELHEIM, DE Inventor name: KANDOLF, REINHARD, PROF. DR., 72379 HECHINGEN, DE Inventor name: MEYER-FICCA, MIRELLA, 72810 GOMARINGEN, DE |
|
8127 | New person/name/address of the applicant |
Owner name: HEART BIOSYSTEMS GMBH, 69120 HEIDELBERG, DE |
|
8181 | Inventor (new situation) |
Inventor name: KUEPPER, JAN-HEINER, DR., 47574 GOCH, DE Inventor name: MEYER, RALPH, DR., 55596 WALDBOECKELHEIM, DE Inventor name: MEYER-FICCA, MIRELLA, 72810 GOMARINGEN, DE Inventor name: KANDOLF, REINHARD, PROF. DR., 72379 HECHINGEN, DE |
|
8139 | Disposal/non-payment of the annual fee |